<Blinded Review: TIME_ANON_0800>
**Composite Score:** 3.1 / 10.0 (Rigor: 0.9/3.5 | Claims: 0.8/2.5 | Biology: 0.8/2.0 | Reproducibility: 0.6/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Commodity/Hype-Cycle Template
**Epistemic Stage:** Translational/Preclinical/Biomarker

OVERALL_SCORE: 3.1/10
VERDICT: FAILED
ESTIMATED_DECADE: 2010s

---

### 1. Executive Summary (SUMMARY)
This study investigates `lncRNA-HIF2PUT` (`TCONS_00004241`), a promoter upstream transcript (PROMPT) transcribed antisense to the *HIF-2$\alpha$* (*EPAS1*) promoter at chromosome 2p21, in colorectal cancer (CRC) clinical specimens and cell lines. Following the exact template of the authors' prior report on the same transcript in osteosarcoma (ref. 16), the manuscript measures `lncRNA-HIF2PUT` and *HIF-2$\alpha$* mRNA by SYBR-Green RT-qPCR in paired CRC tissues and eight cell lines (FHC plus seven CRC lines), and evaluates a single siRNA targeting `lncRNA-HIF2PUT` in serum-free sphere-enriched DLD-1 and HT29 cells across RT-qPCR/Western blot (*HIF-2$\alpha$*, *OCT4*, *SOX2*, *CD44*), colony formation, spheroid formation, scratch wound healing, and Matrigel transwell invasion assays. Audit of the manuscript reveals pervasive methodological, technical, and reporting failures: contradictory patient sample sizes between sections ($N=23$ vs. $N=20$), complete omission of Table 1 (leaving all RT-qPCR primer sequences unreported), complete omission of primary antibody identities/catalog numbers for Western blotting, reliance on a single siRNA without off-target or rescue controls, and a flawed scratch-wound protocol in which monolayers were wounded *prior* to siRNA transfection.

### 2. Methodological & Statistical Audit (STRENGTHS, WEAKNESSES & METHODOLOGICAL AUDIT)
**Strengths:**
* **Paired Tumor/Normal Tissue & Multi-Cell-Line Screening:** Co-expression of `lncRNA-HIF2PUT` and *HIF-2$\alpha$* is evaluated in both patient tumor/adjacent-normal pairs and a panel of seven CRC cell lines relative to normal colonic epithelial FHC cells, with phenotypic assays replicated in two independent CRC cell lines (DLD-1 and HT29).

**Weaknesses & Methodological Audit:**
* **Internal Contradiction in Patient Sample Size ($N=23$ vs. $N=20$):** In the Introduction (line 20), the authors state: *"in the current study, we investigated the expression pattern of the lncRNA/mRNA gene pairs of lncRNA-HIF2PUT and HIF-2$\alpha$ in **23** CRC specimens."* However, in Results (line 83) and Discussion (line 102), they state: *"LncRNA-HIF2PUT and HIF-2$\alpha$ expression levels were assessed in a group of **20** patients with CRC."* No explanation is given for the disappearance of 3 patients.
* **Missing Table 1 (Complete Absence of RT-qPCR Primer Sequences):** Materials and Methods ("Real-time quantitative polymerase chain reaction", line 38) states: *"The primers were obtained from Sangon biotech (Shanghai, People's Republic of China), and the sequences are shown in Table 1."* **Table 1 does not exist in the manuscript.** Consequently, none of the primer sequences for `lncRNA-HIF2PUT`, *HIF-2$\alpha$*, *OCT4*, *SOX2*, *CD44*, or *$\beta$-actin* are available.
* **Complete Omission of Western Blot Antibody Identities and Sources:** Materials and Methods ("Western blot analysis", line 45) describes gel electrophoresis and blocking, then states *"membranes were incubated with the primary antibody overnight at 4°C, followed by incubation with the corresponding secondary antibody"* without specifying a single antibody target, clone/catalog number, dilution, or manufacturer. Furthermore, the lysis buffer recipe specifies `40 nM Tris [pH 7.4]` (a $10^6$-fold concentration error for $40\ \text{mM}$ Tris).
* **Single-siRNA Design at an Overlapping Antisense Promoter Locus Without Rescue:** All functional claims rest on a single siRNA duplex (`5'-CAGCCAUCAUGAUGGUACU-3'`, line 50) without a second independent siRNA, antisense oligonucleotide (ASO), or *HIF-2$\alpha$* cDNA rescue control. Because PROMPTs overlap or lie immediately adjacent to the core promoter/5'-UTR of their paired coding gene, introducing a double-stranded siRNA loads both strands into RISC and can directly cleave overlapping 5'-extended *HIF-2$\alpha$* transcripts or induce argonaute-mediated transcriptional silencing at the *HIF-2$\alpha$* promoter.
* **Invalid Scratch Wound Assay Timing & Misnamed Control Groups:**
  1. In Materials and Methods ("Scratch wound healing assay", line 65), the authors state: *"Uniform wounds were scraped in DLD-1 and HT29 epithelial monolayers grown on plastic six-well plates using a pipette tip **before transfection**. The initial gap length (0 hours) and the residual gap length of 24 hours after wounding were calculated."* Scraping a monolayer at $30\text{–}50\%$ confluency (line 50) *before* siRNA transfection and measuring gap closure over the first 24 hours (before siRNA knockdown of target protein is established) is technically invalid.
  2. In Results (line 93), the negative control siRNA group is repeatedly misdescribed as *"the noncancerous group"* (*"compared with the cells in the noncancerous group (Figure 3E)... compared with the noncancerous groups in the DLD-1 and HT29 cell lines (Figure 3F)"*).

### 3. Biological / Experimental Grounding & Claim Proportionality
* **Claim 1 (`lncRNA-HIF2PUT` expression positively correlates with *HIF-2$\alpha$* mRNA in CRC tissues and cell lines): `[Moderately Supported]`** — Positive correlation ($R = 0.5793$ in tissues; $R = 0.983$ across 8 cell lines) is biologically expected for divergent bidirectional transcription from a shared promoter, though undermined by the $N=23$ vs. $N=20$ sample size discrepancy and missing primer sequences.
* **Claim 2 (`lncRNA-HIF2PUT` functions as an upstream regulator of *HIF-2$\alpha$* and mediator of cancer stem cell self-renewal, migration, and invasion in CRC): `[Methodologically Flawed]`** — Relies on a single siRNA at a bidirectional promoter without off-target or *HIF-2$\alpha$* rescue controls, missing qPCR primers and antibody identities, and a pre-transfection wound-healing protocol.

### 4. Reproducibility & Data Completeness
* **Non-Reproducible:** Missing Table 1 (all RT-qPCR primers omitted), unspecified Western blot antibodies, unspecified replicate counts ($n$) for cellular assays, and contradictory patient numbers render the study non-reproducible.
</Blinded Review: TIME_ANON_0800>
